Korean Botox-makers fly high in H1
Aug. 18, 2016
[THE INVESTOR] South Korean biologics company Medytox recorded 50 billion won (US$45.1 million) turnover in the first half this year, its best so far, according to industry sources on Aug. 18.The company best known for Meditoxin, its own version of Botox, and Innotox, a liquid form of the botulinium toxin, sold the flagship products to the tune of 8.4 billion won in the second quarter alone, up 44 percent on-year. Another major product filler’s sales overseas hiked 132 percent to 11.2 billion wo